Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRIME
NCT03953898Phase 2Active, not recruiting
- Sponsor
- National Cancer Institute
- Start
- Aug 2020
- Primary completion
- Jan 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of olaparib in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), sponsored by National Cancer Institute. Primary endpoint: Cumulative Overall Response Rate. Started Aug 2020; status: active, not recruiting.
02
Drugs
olaparib
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT03953898.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03953898.